Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Expression of NY-ESO-1, MAGE-A3, PRAME and WT1 in different subgroups of breast cancer: An indication to immunotherapy?

Tessari A, Pilla L, Silvia D, Duca M, Paolini B, Carcangiu ML, Mariani L, de Braud FG, Cresta S.

Breast. 2018 Dec;42:68-73. doi: 10.1016/j.breast.2018.08.106. Epub 2018 Aug 29.

PMID:
30189381
2.

Immune Profiling of Cancer Patients Treated with Immunotherapy: Advances and Challenges.

Pilla L, Maccalli C.

Biomedicines. 2018 Jul 2;6(3). pii: E76. doi: 10.3390/biomedicines6030076. Review.

3.

Methods for improving the immunogenicity and efficacy of cancer vaccines.

Pilla L, Ferrone S, Maccalli C.

Expert Opin Biol Ther. 2018 Jul;18(7):765-784. doi: 10.1080/14712598.2018.1485649. Epub 2018 Jun 17. Review.

PMID:
29874943
4.

Brugada Phenocopy induced by recurrent hyperkalemia: More evidence for the reproducibility of a new phenomenon.

Neto NO, Pilla L, Oliveira WS, Velloso RN, Maia FG, do Nascimento AL, Mastrocola F.

J Electrocardiol. 2018 May - Jun;51(3):402-404. doi: 10.1016/j.jelectrocard.2018.02.017. Epub 2018 Mar 7. No abstract available.

PMID:
29550103
5.

Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study.

Maccalli C, Giannarelli D, Capocefalo F, Pilla L, Fonsatti E, Di Giacomo AM, Parmiani G, Maio M.

Oncoimmunology. 2015 Aug 12;5(2):e1071007. eCollection 2016 Feb.

6.

Intra-Household Nutritional Dynamics: A Cross-Sectional Study of Maasai Communities in Kenya.

Pilla L, Dantas JA.

Qual Health Res. 2016 May;26(6):793-806. doi: 10.1177/1049732316629111. Epub 2016 Feb 9.

PMID:
26861897
7.

"Cancer Bio-Immunotherapy in Siena": Twelfth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 9-11, 2014.

Maio M, Bertocci E, Pilla L, Fazio C, Chiarucci C, Cutaia O, Fonsatti E, Maccalli C, Parmiani G; NIBIT.

Cancer Immunol Immunother. 2016 Jan;65(1):119-26. doi: 10.1007/s00262-015-1699-z. Epub 2015 May 6. No abstract available.

PMID:
25944004
8.

A pilot Phase I study combining peptide-based vaccination and NGR-hTNF vessel targeting therapy in metastatic melanoma.

Parmiani G, Pilla L, Corti A, Doglioni C, Cimminiello C, Bellone M, Parolini D, Russo V, Capocefalo F, Maccalli C.

Oncoimmunology. 2014 Dec 21;3(11):e963406. eCollection 2014 Nov.

9.

Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study.

Di Giacomo AM, Ascierto PA, Queirolo P, Pilla L, Ridolfi R, Santinami M, Testori A, Simeone E, Guidoboni M, Maurichi A, Orgiano L, Spadola G, Del Vecchio M, Danielli R, Calabrò L, Annesi D, Giannarelli D, Maccalli C, Fonsatti E, Parmiani G, Maio M.

Ann Oncol. 2015 Apr;26(4):798-803. doi: 10.1093/annonc/mdu577. Epub 2014 Dec 23.

PMID:
25538176
10.

Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response.

Camisaschi C, Filipazzi P, Tazzari M, Casati C, Beretta V, Pilla L, Patuzzo R, Maurichi A, Cova A, Maio M, Chiarion-Sileni V, Tragni G, Santinami M, Vergani B, Villa A, Berti E, Umansky L, Beckhove P, Umansky V, Parmiani G, Rivoltini L, Castelli C.

Cancer Immunol Immunother. 2013 May;62(5):897-908. doi: 10.1007/s00262-013-1397-7. Epub 2013 Apr 16.

11.

Clinical and immunologic responses in melanoma patients vaccinated with MAGE-A3-genetically modified lymphocytes.

Russo V, Pilla L, Lunghi F, Crocchiolo R, Greco R, Ciceri F, Maggioni D, Fontana R, Mukenge S, Rivoltini L, Rigamonti G, Mercuri SR, Nicoletti R, Maschio AD, Gianolli L, Fazio F, Marchianò A, Florio AD, Maio M, Salomoni M, Gallo-Stampino C, Fiacco MD, Lambiase A, Coulie PG, Patuzzo R, Parmiani G, Traversari C, Bordignon C, Santinami M, Bregni M.

Int J Cancer. 2013 Jun 1;132(11):2557-66. doi: 10.1002/ijc.27939. Epub 2012 Dec 13.

12.

Limited induction of tumor cross-reactive T cells without a measurable clinical benefit in early melanoma patients vaccinated with human leukocyte antigen class I-modified peptides.

Filipazzi P, Pilla L, Mariani L, Patuzzo R, Castelli C, Camisaschi C, Maurichi A, Cova A, Rigamonti G, Giardino F, Di Florio A, Asioli M, Frati P, Sovena G, Squarcina P, Maio M, Danielli R, Chiarion-Sileni V, Villa A, Lombardo C, Tragni G, Santinami M, Parmiani G, Rivoltini L.

Clin Cancer Res. 2012 Dec 1;18(23):6485-96. doi: 10.1158/1078-0432.CCR-12-1516. Epub 2012 Oct 2.

13.

Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial.

Di Giacomo AM, Ascierto PA, Pilla L, Santinami M, Ferrucci PF, Giannarelli D, Marasco A, Rivoltini L, Simeone E, Nicoletti SV, Fonsatti E, Annesi D, Queirolo P, Testori A, Ridolfi R, Parmiani G, Maio M.

Lancet Oncol. 2012 Sep;13(9):879-86. doi: 10.1016/S1470-2045(12)70324-8. Epub 2012 Aug 13.

PMID:
22894884
14.

Transarterial chemoembolization with drug-eluting beads preloaded with irinotecan as a first-line approach in uveal melanoma liver metastases: tumor response and predictive value of diffusion-weighted MR imaging in five patients.

Venturini M, Pilla L, Agostini G, Cappio S, Losio C, Orsi M, Ratti F, Aldrighetti L, De Cobelli F, Del Maschio A.

J Vasc Interv Radiol. 2012 Jul;23(7):937-41. doi: 10.1016/j.jvir.2012.04.027.

PMID:
22720894
15.

Ex vivo enrichment of circulating anti-tumor T cells from both cutaneous and ocular melanoma patients: clinical implications for adoptive cell transfer therapy.

Mazzarella T, Cambiaghi V, Rizzo N, Pilla L, Parolini D, Orsenigo E, Colucci A, Modorati G, Doglioni C, Parmiani G, Maccalli C.

Cancer Immunol Immunother. 2012 Aug;61(8):1169-82. doi: 10.1007/s00262-011-1179-z. Epub 2011 Dec 30.

16.

Autologous versus allogeneic cell-based vaccines?

Parmiani G, Pilla L, Maccalli C, Russo V.

Cancer J. 2011 Sep-Oct;17(5):331-6. doi: 10.1097/PPO.0b013e3182337a76. Review.

PMID:
21952283
17.

Severe pulmonary arterial hypertension in a very premature baby with bronchopulmonary dysplasia: normalization with long-term sildenafil.

Caputo S, Furcolo G, Rabuano R, Basilicata AM, Pilla LM, De Simone A, Pasquariello B, Ciampi Q, Vetrano G, Villari B.

J Cardiovasc Med (Hagerstown). 2010 Sep;11(9):704-6. doi: 10.2459/JCM.0b013e328332e745.

PMID:
19829144
18.

Multipeptide vaccination in cancer patients.

Pilla L, Rivoltini L, Patuzzo R, Marrari A, Valdagni R, Parmiani G.

Expert Opin Biol Ther. 2009 Aug;9(8):1043-55. doi: 10.1517/14712590903085109. Review.

PMID:
19591629
19.

Visual confirmation.

Pilla LA.

Health Manag Technol. 2008 Sep;29(9):34-6. No abstract available.

PMID:
18795742
20.

Universal and stemness-related tumor antigens: potential use in cancer immunotherapy.

Parmiani G, Russo V, Marrari A, Cutolo G, Casati C, Pilla L, Maccalli C, Rivoltini L, Castelli C.

Clin Cancer Res. 2007 Oct 1;13(19):5675-9. No abstract available.

21.

Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine.

Filipazzi P, Valenti R, Huber V, Pilla L, Canese P, Iero M, Castelli C, Mariani L, Parmiani G, Rivoltini L.

J Clin Oncol. 2007 Jun 20;25(18):2546-53.

PMID:
17577033
22.

Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients.

Parmiani G, Castelli C, Pilla L, Santinami M, Colombo MP, Rivoltini L.

Ann Oncol. 2007 Feb;18(2):226-32. Epub 2006 Nov 20. Review.

PMID:
17116643
23.

Vaccination therapy in prostate cancer.

Marrari A, Iero M, Pilla L, Villa S, Salvioni R, Valdagni R, Parmiani G, Rivoltini L.

Cancer Immunol Immunother. 2007 Apr;56(4):429-45. Epub 2006 Oct 10. Review.

PMID:
17031640
24.

Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes.

Valenti R, Huber V, Filipazzi P, Pilla L, Sovena G, Villa A, Corbelli A, Fais S, Parmiani G, Rivoltini L.

Cancer Res. 2006 Sep 15;66(18):9290-8.

25.

Vaccination: role in metastatic melanoma.

Pilla L, Valenti R, Marrari A, Patuzzo R, Santinami M, Parmiani G, Rivoltini L.

Expert Rev Anticancer Ther. 2006 Aug;6(8):1305-18. Review.

PMID:
16925496
26.

Heat shock proteins gp96 as immunogens in cancer patients.

Parmiani G, De Filippo A, Pilla L, Castelli C, Rivoltini L.

Int J Hyperthermia. 2006 May;22(3):223-7.

PMID:
16754342
27.

Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors.

Di Pucchio T, Pilla L, Capone I, Ferrantini M, Montefiore E, Urbani F, Patuzzo R, Pennacchioli E, Santinami M, Cova A, Sovena G, Arienti F, Lombardo C, Lombardi A, Caporaso P, D'Atri S, Marchetti P, Bonmassar E, Parmiani G, Belardelli F, Rivoltini L.

Cancer Res. 2006 May 1;66(9):4943-51.

28.

A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients.

Pilla L, Patuzzo R, Rivoltini L, Maio M, Pennacchioli E, Lamaj E, Maurichi A, Massarut S, Marchianò A, Santantonio C, Tosi D, Arienti F, Cova A, Sovena G, Piris A, Nonaka D, Bersani I, Di Florio A, Luigi M, Srivastava PK, Hoos A, Santinami M, Parmiani G.

Cancer Immunol Immunother. 2006 Aug;55(8):958-68. Epub 2005 Oct 8.

PMID:
16215718
29.

Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control?

Rivoltini L, Canese P, Huber V, Iero M, Pilla L, Valenti R, Fais S, Lozupone F, Casati C, Castelli C, Parmiani G.

Expert Opin Biol Ther. 2005 Apr;5(4):463-76. Review.

PMID:
15934826
30.

Natural killer and NK-Like T-cell activation in colorectal carcinoma patients treated with autologous tumor-derived heat shock protein 96.

Pilla L, Squarcina P, Coppa J, Mazzaferro V, Huber V, Pende D, Maccalli C, Sovena G, Mariani L, Castelli C, Parmiani G, Rivoltini L.

Cancer Res. 2005 May 1;65(9):3942-9.

31.

Heat shock proteins and their use as anticancer vaccines.

Parmiani G, Testori A, Maio M, Castelli C, Rivoltini L, Pilla L, Belli F, Mazzaferro V, Coppa J, Patuzzo R, Sertoli MR, Hoos A, Srivastava PK, Santinami M.

Clin Cancer Res. 2004 Dec 15;10(24):8142-6. Review. No abstract available.

32.

Role of cross-talk between IFN-alpha-induced monocyte-derived dendritic cells and NK cells in priming CD8+ T cell responses against human tumor antigens.

Tosi D, Valenti R, Cova A, Sovena G, Huber V, Pilla L, Arienti F, Belardelli F, Parmiani G, Rivoltini L.

J Immunol. 2004 May 1;172(9):5363-70.

33.

IFNalpha-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells.

Tecchio C, Huber V, Scapini P, Calzetti F, Margotto D, Todeschini G, Pilla L, Martinelli G, Pizzolo G, Rivoltini L, Cassatella MA.

Blood. 2004 May 15;103(10):3837-44. Epub 2004 Jan 15.

PMID:
14726404
34.

Human tumor-derived heat shock protein 96 mediates in vitro activation and in vivo expansion of melanoma- and colon carcinoma-specific T cells.

Rivoltini L, Castelli C, Carrabba M, Mazzaferro V, Pilla L, Huber V, Coppa J, Gallino G, Scheibenbogen C, Squarcina P, Cova A, Camerini R, Lewis JJ, Srivastava PK, Parmiani G.

J Immunol. 2003 Oct 1;171(7):3467-74.

35.

Vaccination of patients with solid tumours.

Parmiani G, Pilla L, Castelli C, Rivoltini L.

Ann Oncol. 2003 Jun;14(6):817-24. Review.

PMID:
12796017
36.

Money matters: results of the 2002 NP salary survey.

Pilla L.

Nurse Pract. 2003 Apr;28(4):32-6. No abstract available.

PMID:
12682520
37.

Suboptimal activation of CD8(+) T cells by melanoma-derived altered peptide ligands: role of Melan-A/MART-1 optimized analogues.

Carrabba MG, Castelli C, Maeurer MJ, Squarcina P, Cova A, Pilla L, Renkvist N, Parmiani G, Rivoltini L.

Cancer Res. 2003 Apr 1;63(7):1560-7.

38.

Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings.

Belli F, Testori A, Rivoltini L, Maio M, Andreola G, Sertoli MR, Gallino G, Piris A, Cattelan A, Lazzari I, Carrabba M, Scita G, Santantonio C, Pilla L, Tragni G, Lombardo C, Arienti F, Marchianò A, Queirolo P, Bertolini F, Cova A, Lamaj E, Ascani L, Camerini R, Corsi M, Cascinelli N, Lewis JJ, Srivastava P, Parmiani G.

J Clin Oncol. 2002 Oct 15;20(20):4169-80. Erratum in: J Clin Oncol 2002 Dec 1;20(23):4610.

PMID:
12377960
39.

Nursing and the press.

Pilla LM.

Nursing. 1997 Feb;27(2):62-4. No abstract available.

PMID:
9171610
40.

Comparative in vitro spermicidal effects of (+/-)-gossypol, (+)-gossypol, (-)-gossypol and gossypolone.

Kim IC, Waller DP, Marcelle GB, Cordell GA, Fong HH, Pirkle WH, Pilla L, Matlin SA.

Contraception. 1984 Sep;30(3):253-9.

PMID:
6509980
41.

[Goltz syndrome (focal dermal hypoplasia): a case report (author's transl)].

Sellitto F, Zeppa M, Scarano G, Pilla LM, Angrisani P, Galluccio A.

Pediatr Med Chir. 1981 Nov-Dec;3(6):563-6. Italian. No abstract available.

PMID:
6806785
42.

Radiotherapy in the treatment of bladder cancer. A preliminary report.

Stanley RJ, Francisco DS, Pilla LA.

Mo Med. 1970 Jun;67(6):363-5. No abstract available.

PMID:
5444389
43.

INTRAUTERINE TRANSFUSION OF ERYTHROBLASTOTIC FETUS. CASE REPORT.

HAMILTON EG, PILLA LA.

Mo Med. 1965 Aug;62:682-4. No abstract available.

PMID:
14339779
44.

Agglomeration of barium sulfate and roentgen visualization of the gastric mucosa.

KNOEFEL PK, DAVIS LA, PILLA LA.

Radiology. 1956 Jul;67(1):87-91. No abstract available.

PMID:
13336326
45.

Non-malignant roentgen changes in the gastro-intestinal tract associated with aging.

PIRKEY EL, PILLA LA, PIPKIN DE.

South Med J. 1953 May;46(5):446-9. No abstract available.

PMID:
13056792
46.

Preoperative and postoperative cholangiography.

PIRKEY EL, DAVIS LA, PILLA LA.

J Am Med Assoc. 1953 Jan 24;151(4):266-8. No abstract available.

PMID:
12999550
47.

Mulsopaque for the circumferential outlining of empyema cavities.

PIRKEY EL, DAVIS LA, PILLA LA.

Med Radiogr Photogr. 1953;29(1):20-1. No abstract available.

PMID:
13054066

Supplemental Content

Support Center